Horizon Therapeutics (Horizon Therapeutics) Days Sales Outstanding : 64.80 (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Days Sales Outstanding?

Horizon Therapeutics's average Accounts Receivable for the three months ended in Jun. 2023 was $671 Mil. Horizon Therapeutics's Revenue for the three months ended in Jun. 2023 was $945 Mil. Hence, Horizon Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2023 was 64.80.

The historical rank and industry rank for Horizon Therapeutics's Days Sales Outstanding or its related term are showing as below:

HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.89 Med: 80.86 Max: 131.47
Current: 66.87

During the past 13 years, Horizon Therapeutics's highest Days Sales Outstanding was 131.47. The lowest was 47.89. And the median was 80.86.

HZNP's Days Sales Outstanding is not ranked
in the Drug Manufacturers industry.
Industry Median: 71.68 vs HZNP: 66.87

Horizon Therapeutics's Days Sales Outstanding declined from Jun. 2022 (70.69) to Jun. 2023 (64.80).

Horizon Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Horizon Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Days Sales Outstanding Chart

Horizon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

131.47

122.61

88.61

73.11

65.83

Horizon Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Sales Outstanding	Get a 7-Day Free Trial															70.69	65.07	64.06	71.34	64.80

Competitive Comparison of Horizon Therapeutics's Days Sales Outstanding

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Horizon Therapeutics's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Days Sales Outstanding falls into.

Horizon Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Horizon Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (632.775	+	676.347)	/	2 )	/	3629.044	*	365
=	654.561					/	3629.044	*	365
=	65.83

Horizon Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding (Q: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2023 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (624.697	+	717.417)	/	2 )	/	944.959	*	365 / 4
=	671.057					/	944.959	*	365 / 4
=	64.80

Horizon Therapeutics (NAS:HZNP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Horizon Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Horizon Therapeutics (Horizon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 St. Stephen’s Green, Dublin, IRL, D02 E2X4

Website

https://www.horizontherapeutics.com

Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Executives

Andy Pasternak	officer: EVP and Chief Business Officer	C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox	officer: EVP, Chief Financial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman	officer: EVP & Chief Medical Officer	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny	officer: Chief Accounting Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton	officer: EVP, General Counsel	C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z.	officer: EVP, Research & Development	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director, officer: President, Chairman and CEO	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi	officer: Chief Commercial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher	officer: EVP Finance	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin	officer: EVP, Technical Operations	C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh	officer: Principal Accounting Officer	C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze	officer: EVP, Corporate Dev't.	C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler	officer: EVP, General Counsel	C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel	director	TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000